trial
as of 2026-07-01A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
NCTId NCT00839852
at a glance
Phase 2 · Completed
Enrollment 97 (actual)
Sponsored by Forest Laboratories
Primary completion 2010-08-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
97 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2009-05-31
Primary completion
2010-08-31
Eligibility
ALL · 18 Years · 61 Years
Interventions & indications
Indications
Sponsors
Forest LaboratoriesLead Sponsor
Gedeon Richter Ltd.Collaborator
Investigators
1
Suresh Durgam, MDStudy Director
Sites
65 total
Costa Mesa, United StatesLong Beach, United StatesOceanside, United StatesParamount, United StatesRiverside, United StatesWashington D.C., United StatesBradenton, United StatesKissimmee, United StatesLake Charles, United StatesBaltimore, United StatesFlowood, United StatesCreve Coeur, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
97
Phase
PHASE2
Primary Completion Date
2010-08-31
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
company
indication
indication
indication
investigator
person